{"id":243013,"date":"2026-08-21T05:05:55","date_gmt":"2026-08-21T10:05:55","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/08\/investigational-daily-pill-doubles-survival-in-metastatic-pancreatic-cancer-study-shows"},"modified":"2026-08-21T05:05:55","modified_gmt":"2026-08-21T10:05:55","slug":"investigational-daily-pill-doubles-survival-in-metastatic-pancreatic-cancer-study-shows","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/08\/investigational-daily-pill-doubles-survival-in-metastatic-pancreatic-cancer-study-shows","title":{"rendered":"Investigational daily pill doubles survival in metastatic pancreatic cancer, study shows"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/investigational-daily-pill-doubles-survival-in-metastatic-pancreatic-cancer-study-shows.jpg\"><\/a><\/p>\n<p>In an international study co-led by UCLA, investigators found an investigational targeted therapy significantly extended overall survival for patients with previously treated metastatic pancreatic cancer and reduced the risk of death by 60% compared with standard chemotherapy in both the RAS G12 and the overall, or intent-to-treat (ITT) population, which included patients with and without identified tumor RAS mutations.<\/p>\n<p>The team found patients who received the drug daraxonrasib, an investigational, first-in-class oral RAS(ON) multi-selective inhibitor designed to block active RAS signaling \u2014 one of the primary drivers of pancreatic cancer \u2014 lived a median of 13.2 months compared with 6.7 months for those who received investigator\u2019s choice chemotherapy in the RAS G12 population.<\/p>\n<p>The findings suggest a potential investigational treatment option for patients with metastatic pancreatic cancer, a disease that remains among the most lethal cancers and has limited effective therapies.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In an international study co-led by UCLA, investigators found an investigational targeted therapy significantly extended overall survival for patients with previously treated metastatic pancreatic cancer and reduced the risk of death by 60% compared with standard chemotherapy in both the RAS G12 and the overall, or intent-to-treat (ITT) population, which included patients with and without [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-243013","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/243013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=243013"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/243013\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=243013"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=243013"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=243013"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}